Literature DB >> 15907544

Influenza vaccine coverage in paediatric population from central Israel.

M Stein1, O Yossepowitch, E Somekh.   

Abstract

OBJECTIVES: The aim of this study was to estimate the influenza vaccine coverage among children attending paediatric ER.
METHODS: The parents of patients attending paediatric ER during the winter of 2003-2004 were inquired about their children's influenza vaccination status, whether the vaccine was recommended by the primary paediatrician recommendation, the medical history, and about several epidemiological details.
RESULTS: Total of 557 questionnaires were completed. Mean age was 5.8 years. Only 23 of the 557 patients were vaccinated (4.1% coverage). Vaccine coverage in the 107 children from high risk groups was 6.5% and vaccination rate in the 144 infants aged 6-24 months was 2.7%. Influenza vaccine was recommended by the primary paediatricians in 59 cases (10.6%). Vaccine was recommended to 22.4% of patients from high risk groups, to 7.6% of infants aged 6-24 months of age and to 7.8% of the other children.
CONCLUSIONS: Influenza vaccine coverage among Israeli children is low, including patients from high-risk groups, and awareness of the primary paediatricians seems to be unsatisfactory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907544     DOI: 10.1016/j.jinf.2005.01.017

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  2 in total

1.  Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine.

Authors:  Huakun Lv; Xuejiao Pan; Hui Liang; Ying Wang; Yu Hu
Journal:  Hum Vaccin Immunother       Date:  2021-09-07       Impact factor: 4.526

Review 2.  Influenza vaccine coverage among children under the age of 5 years in Poland during 2004-2008.

Authors:  Aneta Nitsch-Osuch; E Kuchar; K Zycinska; A Topczewska-Cabanek; E Gyrczuk; K Wardyn
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.